Document Detail


The effects of topical corticosteroids and a coal tar preparation on dithranol-induced irritation in patients with psoriasis.
MedLine Citation:
PMID:  12566824     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dithranol has been a mainstay in the treatment of psoriasis for more than 80 years. Although a safe approach, the irritation of the clinically uninvolved perilesional skin remains a major limitation of this treatment. Corticosteroids and coal tar solution have an anti-inflammatory potential. The aim of the present study was to investigate the clinical and cell-biological effects of two topical corticosteroids and a coal tar preparation on dithranol-irritated skin. During 4 consecutive days, 2% dithranol cream was applied to six uninvolved skin sites (3 cm in diameter) on the lower back of 9 patients with psoriasis. Dithranol was left on the skin for 1 h, subsequently removed with water and soap and the skin was dried with a towel. Subsequently, SITE 1 was treated with 0.05% clobetasol-17-propionate ointment (CP), SITE 2 with unguentum cetomacrogolis (vehicle 1), SITE 3 with 0.005% fluticasonpropionate ointment (FP), SITE 4 with 10% coal tar solution in lanettewax cream (CTS), SITE 5 was left untreated (control) and SITE 6 was treated with lanettewax cream (vehicle 2). Erythema, oedema and vesicle formation was scored every day. On day 5, punch biopsies were taken from the six sites. The expression of epidermal proliferation, differentiation and inflammation markers and the clinical irritation scores indicate that the application of a high potency corticosteroid (CP) is the best approach to minimise dithranol irritation, whereas CTS had virtually no effect on dithranol irritation during this 4-day experimental model.
Authors:
O Q J Swinkels; M Kucharekova; M Prins; M J P Gerritsen; P G M van der Valk; P C M van de Kerkhof
Related Documents :
16313244 - Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris.
19573024 - Adalimumab for psoriasis patients who are non-responders to etanercept: open-label pros...
16699904 - Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from...
18284264 - Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-t...
16313244 - Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris.
21331544 - Economic evaluation of nsaid and radiation to prevent heterotopic ossification after hi...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Skin pharmacology and applied skin physiology     Volume:  16     ISSN:  1422-2868     ISO Abbreviation:  Skin Pharmacol. Appl. Skin Physiol.     Publication Date:    2003 Jan-Feb
Date Detail:
Created Date:  2003-02-04     Completed Date:  2003-09-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9807277     Medline TA:  Skin Pharmacol Appl Skin Physiol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  12-7     Citation Subset:  IM    
Copyright Information:
Copyright 2003 S. Karger AG, Basel
Affiliation:
Department of Dermatology University Medical Centre Nijmegen, Nijmegen, The Netherlands. O.Swinkels@derma.azn.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adult
Aged
Aged, 80 and over
Androstadienes / administration & dosage,  therapeutic use
Anthralin / administration & dosage,  adverse effects*,  therapeutic use
Anti-Inflammatory Agents / administration & dosage,  adverse effects*,  therapeutic use*
Cell Division / drug effects
Clobetasol / administration & dosage,  analogs & derivatives*,  therapeutic use
Coal Tar / administration & dosage,  therapeutic use*
Erythema / chemically induced,  drug therapy*
Female
Glucocorticoids
Humans
Macrophages / drug effects
Male
Middle Aged
Monocytes / drug effects
Psoriasis / drug therapy*
Skin / drug effects,  pathology
T-Lymphocytes / drug effects
Vehicles
Chemical
Reg. No./Substance:
0/Androstadienes; 0/Anti-Inflammatory Agents; 0/Glucocorticoids; 0/Vehicles; 25122-41-2/Clobetasol; 480-22-8/Anthralin; 8007-45-2/Coal Tar; 90566-53-3/fluticasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy measurement of topical antihistamines: a review.
Next Document:  In vivo tolerance assessment of skin after insertion of subcutaneous and cutaneous microdialysis pro...